MS4A1 and B-cell non-Hodgkin lymphoma: A secondary goal was to identify MS4A proteins that might provide alternate therapeutic targets for chronic lymphocytic leukemia (CLL), a B-cell malignancy in which CD20 is expressed at much lower levels than in B-cell lymphomas (22, –24).